Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

D-SOLVE

Financiado

Understanding the individual host response against Hepatitis D Virus to develop...

Understanding the individual host response against Hepatitis D Virus to develop a personalized approach for the management of hepatitis D Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection of hepatitis B patients with the hepatitis D virus... ver más

30/09/2026

MHH

7M€

Presupuesto del proyecto: 7M€

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-25

HORIZON-HLTH-2021-DISEASE-04-07: Personalised medicine and infectiou... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100% 100%

8 Participantes

MHH

1.92M€ | Lider

INSERM

562.95K€ | Participante

TAT

372.50K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2015-70028-R DESARROLLO Y CARACTERIZACION DE UN MODELO DE INFECCION CRONI... Cerrado

SAF2013-44282-R ESTUDIO DE LA IMPLICACION DE FACTORES CELULARES EN LA INFECC... 61K€ Cerrado

RTI2018-101936-B-I00 ANALISIS DE LA INTERACION DEL VIRUS DE LA HEPATITIS DELTA (H... 339K€ Cerrado

PID2020-118970RB-I00 ESTUDIO DE LOS DETERMINANTES VIRALES Y CELULARES RESPONSABLE... 230K€ Cerrado

SAF2010-19270 ESTUDIO DE GENES CELULARES QUE REGULAN LA INFECCION POR EL V... 157K€ Cerrado

SAF2016-75169-R REGULACION DE LA INFECCION DEL VIRUS DE LA HEPATITIS B POR P... 145K€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2022-05-25
Fecha Fin: 2026-09-30

Líder del proyecto

MEDIZINISCHE HOCHSCHULE HANNOVER No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 7M€

Descripción del proyecto Hepatitis D is by far the most severe form of chronic viral hepatitis frequently leading to liver failure, hepatocellular carcinoma and death. Hepatitis D is caused by coinfection of hepatitis B patients with the hepatitis D virus (HDV). Up to 20 Million individuals are infected with HDV worldwide including about 250.000 patients in the European Union. There is very limited knowledge on disease pathophysiology and host-virus interactions explaining the large interindividual variability in the course of hepatitis D. It is in particular unknown why 20-50% are spontaneously able to control HDV replication, why the majority but not all patients progress to advanced stages of liver disease and why only some patients show off-treatment responses to antiviral treatment with either pegylated interferon alpha or the novel HBV/HDV entry inhibitor bulevirtide. As HDV is an orphan disease, no multicenter cohorts of HDV infected patients are available with appropriate biobanking. There is also no reliable animal model available allowing to study host responses. Thus, there is an urgent clinical, social and economic need to better understand individual factors determining the outcome of infection and to identify subjects benefitting from currently available treatments. Hepatitis D is a protype infection which could hugely benefit from a novel individualized infectious medicine approach. We here aim to perform an unbiased screening of a large multicenter cohort of well-defined HDV-infected patients followed by mechanistic studies to determine the functional role of distinct molecules. Identified specific parameters could have an immediate impact on the personalized surveillance strategies and antiviral treatment approaches. D-SOLVE aims to reduce disease burden, improve patient?s quality of life and safe direct and indirect costs caused by HDV infection by combining exceptional clinical, immunological, bioinformatical and virological expertise from leading centers in Europe.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores